WO2012087835A2 - Compositions et procédés pour favoriser le repliement d'une protéine - Google Patents
Compositions et procédés pour favoriser le repliement d'une protéine Download PDFInfo
- Publication number
- WO2012087835A2 WO2012087835A2 PCT/US2011/065563 US2011065563W WO2012087835A2 WO 2012087835 A2 WO2012087835 A2 WO 2012087835A2 US 2011065563 W US2011065563 W US 2011065563W WO 2012087835 A2 WO2012087835 A2 WO 2012087835A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- bag
- predicted
- polypeptide
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions et des procédés qui favorisent le repliement d'une protéine, comprenant un domaine BAG.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426326P | 2010-12-22 | 2010-12-22 | |
| US61/426,326 | 2010-12-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012087835A2 true WO2012087835A2 (fr) | 2012-06-28 |
| WO2012087835A3 WO2012087835A3 (fr) | 2012-11-01 |
Family
ID=46314784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/065563 WO2012087835A2 (fr) | 2010-12-22 | 2011-12-16 | Compositions et procédés pour favoriser le repliement d'une protéine |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012087835A2 (fr) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089375A1 (fr) | 2012-12-05 | 2014-06-12 | Boston Strategics Corporation | Polypeptides améliorant l'expression protéique |
| WO2015191892A3 (fr) * | 2014-06-11 | 2016-05-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions d'α1-antitrypsine et méthodes de traitement de maladies auto-immunes |
| US10364292B2 (en) | 2014-01-06 | 2019-07-30 | Hoffmann-La Roche Inc. | Monovalent blood brain barrier shuttle modules |
| US10370692B2 (en) | 2013-12-20 | 2019-08-06 | Hoffmann-La Roche Inc. | Recombinant polypeptide production methods |
| US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
| EP3812473A1 (fr) * | 2014-01-31 | 2021-04-28 | Temple University Of The Commonwealth System Of Higher Education | Bag3 comme cible pour le traitement de l'insuffisance cardiaque |
| US11390899B2 (en) | 2016-09-26 | 2022-07-19 | SOLA Biosciences, LLC | Cell-associated secretion-enhancing fusion proteins |
| US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
| US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1695093A1 (fr) * | 2003-12-05 | 2006-08-30 | multimmune GmbH | Compositions et procedes pour traiter et diagnostiquer des maladies neoplasiques et infectieuses |
| JP2005229874A (ja) * | 2004-02-18 | 2005-09-02 | Institute Of Physical & Chemical Research | Ｂａｇ３ドメインポリペプチド及びその用途 |
-
2011
- 2011-12-16 WO PCT/US2011/065563 patent/WO2012087835A2/fr active Application Filing
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
| WO2014089375A1 (fr) | 2012-12-05 | 2014-06-12 | Boston Strategics Corporation | Polypeptides améliorant l'expression protéique |
| US10370692B2 (en) | 2013-12-20 | 2019-08-06 | Hoffmann-La Roche Inc. | Recombinant polypeptide production methods |
| US10364292B2 (en) | 2014-01-06 | 2019-07-30 | Hoffmann-La Roche Inc. | Monovalent blood brain barrier shuttle modules |
| US11542555B2 (en) | 2014-01-31 | 2023-01-03 | Temple University Of The Commonwealth System Of Higher Education | BAG3 as a target for therapy of heart failure |
| EP3812473A1 (fr) * | 2014-01-31 | 2021-04-28 | Temple University Of The Commonwealth System Of Higher Education | Bag3 comme cible pour le traitement de l'insuffisance cardiaque |
| US11236389B2 (en) * | 2014-01-31 | 2022-02-01 | Temple University Of The Commonwealth System Of Higher Education | BAG3 as a target for therapy of heart failure |
| WO2015191892A3 (fr) * | 2014-06-11 | 2016-05-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions d'α1-antitrypsine et méthodes de traitement de maladies auto-immunes |
| US10781248B2 (en) | 2014-06-11 | 2020-09-22 | Beth Israel Deaconess Medical Center, Inc. | α1-antitrypsin compositions and methods of treating autoimmune diseases |
| US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
| US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
| US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
| US11390899B2 (en) | 2016-09-26 | 2022-07-19 | SOLA Biosciences, LLC | Cell-associated secretion-enhancing fusion proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012087835A3 (fr) | 2012-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012087835A2 (fr) | Compositions et procédés pour favoriser le repliement d'une protéine | |
| Csortos et al. | High complexity in the expression of the B′ subunit of protein phosphatase 2A0: Evidence for the existence of at least seven novel isoforms | |
| US20180372750A1 (en) | Antibody and antibody mimetic for visualization and ablation of endogenous proteins | |
| EP3098241B1 (fr) | Protéine de fusion inhibant l'angiogenèse ou la croissance et son utilisation | |
| EP3556854A1 (fr) | Variant de transcriptase inverse résistant à la chaleur | |
| WO2010058819A1 (fr) | Peptide capable d’inhiber l’interaction entre l’oncoprotéine mdm2 humaine et la protéine antitumorale p53 humaine, et utilisation associée | |
| US20160251636A1 (en) | New methods to produce active tert | |
| EP2910632B1 (fr) | Enzyme hautement fonctionnelle ayant une spécificité de substrat béta-hexosaminidase b humaine modifiée, et présentant une résistance à la protéase | |
| Stefanovic et al. | Characterization of binding of LARP6 to the 5’stem-loop of collagen mRNAs: implications for synthesis of type I collagen | |
| JP2019530433A (ja) | Ｍｇ５３突然変異体、その作製方法、およびその使用 | |
| AU2012306826B2 (en) | Endostatin mutants with mutations at ATP binding sites | |
| US20170204157A1 (en) | Human fgfr2c extracellular protein as well as coding gene and application thereof | |
| CN106754817B (zh) | 一种重组自分泌运动因子的表达方法 | |
| Mao et al. | Angiotensin 1-7 overexpression mediated by a capsid-optimized AAV8 vector leads to significant growth inhibition of hepatocellular carcinoma in vivo | |
| US7476524B2 (en) | Canine COX-2 nucleic acid molecules | |
| EP4159758A1 (fr) | Protéine de fusion rhfgf21, polynucléotide codant pour la protéine de fusion rhfgf21, composition contenant la protéine de fusion rhfgf21, et utilisation de la protéine de fusion rhfgf21 | |
| EP2841449A2 (fr) | Archéase en tant que membre d'un complexe d'arn ligase | |
| US10450358B2 (en) | Platelet-derived growth factor B mutant, preparation method therefor and use thereof | |
| WO2008110356A2 (fr) | Protéines secrétées à partir du cœur et utilisations de celles-ci | |
| WO2020182768A1 (fr) | Procédé de production de lectines bioactives présentant un rendement amélioré | |
| JP4615230B2 (ja) | ガラクトシルセラミド発現因子−１のｃ領域によるがん細胞転移抑制剤 | |
| Zeev-Ben-Mordehai et al. | Amalgam, an axon guidance Drosophila adhesion protein belonging to the immunoglobulin superfamily: over-expression, purification and biophysical characterization | |
| Rosini et al. | Expression and purification of the human tumor suppressor protein RNASET2 in CHO–S cells | |
| EP3808842A1 (fr) | Composition pharmaceutique pour le traitement d'une immunodéficience complexe sévère comprenant une protéine de fusion d'un peptide de pénétration cellulaire et de l'adénosine désaminase | |
| JP4283531B2 (ja) | マスト細胞の細胞死誘発剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11851423 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct app. not ent. europ. phase |
Ref document number: 11851423 Country of ref document: EP Kind code of ref document: A2 |